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Background:We sought to identify prognostic factors of long-termmortality, speciﬁc for the underlying etiology
of chronic systolic heart failure (CHF).
Methods and results: Between 1995 and 2009 baseline characteristics, treatment and follow-up data from 2318
CHF-patients due to ischemic (ICM; 1100 patients) or dilated cardiomyopathy (DCM; 1218 patients) were pro-
spectively compared. To calculate hazard ratios with 95%-conﬁdence intervals cox regression was used. We
respectively established etiology-speciﬁc multivariable models of independent prognostic factors. During the
follow-up period of up to 14.8 years (mean = 53.1 ± 43.5 months; 10,264 patient-years) 991 deaths (42.8%)
occurred.
In the ICM-cohort, 5-year-survivalwas 53.4% (95%CI: 49.9–56.7%),whereas inDCM-patients itwas higher (68.1%
(95% CI: 65.1–71.0%)). Age, ejection fraction, or hyponatremia were independent predictors formortality in both
cohorts, whereas diabetes, COPD, atrial ﬁbrillation and a heart rate of ≥80/min carried independent predictive
power only in ICM-patients.
Conclusion: This study demonstrates the disparity of prognostic value of clinically derived risk factors between
the two main causes of CHF. The effects of covariables in DCM-patients were lower, suggesting a less modiﬁable
disease through risk factors consideringmortality risk. An etiology-speciﬁc prognostic model may improve accu-
racy of survival estimations in CHF.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
During the past decade, many efforts have been made to generate
reliable prognostic tools for patients suffering from chronic systolic
heart failure (CHF) in order to identify patientswho, in spite of adequate
outpatient heart failure care and guideline adherent pharmacotherapy,inhibitor; ARB, Angiotensin re-
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ndle branch block; NT-proBNP,
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eliability and freedom from bias
land Ltd. This is an open access article uare at high risk of rapid deterioration to a more severe stage of the
disease and eventually to an earlier death. Although the clinical phe-
notype of systolic dysfunction and left ventricular dilation is shared
by dilated cardiomyopathy (DCM) and ischemic cardiomyopathy
(ICM), pathogenesis and genetic causes of these leading CHF etiolo-
gies evidently differ. Pre-clinical and clinical ﬁndings have pointed
towards cause-related speciﬁc risks in CHF [1–7], yet to date most
contemporary risk prediction algorithms used for CHF prognostica-
tion derive from large data sets of general CHF populations [8–10]
and therefore fail to differentiate between DCM and ICM. Emerging
concepts of risk prediction incorporate device therapy, novel bio-
markers or common genetic variants into traditional prediction
models of mortality in CHF and by this may further optimize risk pre-
diction [11–16]. Yet it is likewise conceivable that simple knowledge
of inﬂuential differences of clinical indicators according to the sub-
phenotype of CHF has the potential to increase the accuracy and
robustness of prognostic quantiﬁcation today and thus, set a higher
performance benchmark for future risk models. We sought tonder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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CHF by identifying etiology-speciﬁc prognostic factors routinely
available to clinicians.
2. Methods
2.1. Study setting and sample
Both hospitals included in our analysis (secondary hospital:
Städtisches Klinikum, Ludwigshafen and tertiary hospital: University
Hospital, Heidelberg) are located in the south-west of Germany and
offer heart failure treatment for patients from the nearby community
as well as patients referred from other sites. Data from the participating
clinics was entered into a common registry in a prospective manner.
This registry, the ‘HELUMA heart failure registry’ represents a multi-
site cooperation between the specialized heart failure clinics of the Uni-
versity Hospital Heidelberg, the Klinikum Ludwigshafen and the TKH
Mannheim, Germany. As the participating centers serve asmajor outpa-
tient clinics for a region of approximately 900.000 inhabitants a broad
representation of patients in a “real life” setting is ensured. In the pres-
ent study, we included ambulatory patients with CHF due to ICM or
DCM at the institutions mentioned above, who were diagnosed over a
period of 14 years (1995 until 31 January 2009). Informed consent
was obtained from each patient involved. Patients with acute coronary
syndrome during initial evaluation, asymptomatic patients (NYHA
functional class I), left ventricular ejection fraction (EF) of N40% in echo-
cardiographic measurement, those in whom in-hospital death occurred
or patients with other etiologies of CHF such as heart failure secondary
to valvular, hypertensive or a primary pulmonary disease were exclud-
ed from the present analysis. Included patients were followed up regu-
larly during ambulatory examinations which took place at least once a
year, as well as during every hospitalization in a participating center.
2.2. Data collection
Information about patient characteristics, cardiac history, current in-
vestigations (electrocardiography, echocardiography and others), labo-
ratory measurements and chronic medication was collected during the
index visit. The underlying cause of HF was categorized as ICM on the
basis of a history of MI or the ﬁndings in coronary angiography such
as 1-, 2-, 3-vessel CHD except arteriosclerosis without relevant stenosis
or as DCM deﬁned according to the 1995 WHO deﬁnition of cardiomy-
opathies [17]. DCM is well known to have various underlying causes
such as genetic, infectious, autoimmune, and toxic predispositions and
diseases, which ﬁnally end in the common pathway of ventricular dila-
tation and systolic dysfunction [18].We deﬁned DCM as a disease of ge-
netic and/or idiopathic origin and excluded underlying infectious,
autoimmune and/or toxic causes.
Venous blood samples were taken in the morning after overnight
fasting. N-terminal pro-peptide of brain natriuretic peptide (NT-
proBNP) was measured according to the standard protocol of the fully
automated Elecsys® Roche Diagnostics analyzer at the tertiary center
of Heidelberg since 1995 and at the secondary center of Ludwigshafen
since 1999. Anemia was deﬁned according to the WHO thresholds for
hemoglobin used to deﬁne anemia in adult patients (12.0 g/dl in non-
pregnantwomen; 13.0 g/dl inmen) [19]. The left ventricular internal di-
ameter was measured at end diastole (LVEDD) in echocardiography.
Left ventricular systolic function was determined by the EF through
one of the following methods: the biplane disc summation method
(Simpson rule) in echocardiography or by quantitative measurement
or qualitative estimation in contrast ventriculography during cardiac
catheterization. For functional classiﬁcation we used the well-known
NYHA classiﬁcation. Atrial ﬁbrillation and left branch bundle block
(LBBB) were diagnosed by using a 12-lead-electrocardiogram (ECG)
with respect to the guidelines in ECG diagnostics. Patients were follow-
ed prospectively for a generally unlimited time period. Follow-upinformation on vital status, clinical events and medical treatment was
obtained using standardized case report forms during re-examinations
or by telephone calls at least on a yearly basis. No patient identiﬁcation
was recorded on the case report forms or transferred to the analysis
center. Instead, the hospitals were instructed to keep a log of all includ-
ed patients, in which their names, contact information, and study code
were recorded, in order to enable follow-up. The study was performed
according to the ethical standards of the Declaration of Helsinki.
2.3. Statistical analysis
Patient characteristics are described by percentages and compared
by Chi2/Fisher exact test. The distributions of metrical variables are
presented as median and quartiles, metrical or ordinal variables
compared by Mann–Whitney–Wilcoxon U-Test. Death from any cause
constituted the primary endpoint of the study. Density curves for age
were smoothed using triangular kernels. Patients receiving orthotopic
heart transplantation (HTX) were followed until their surgical proce-
dure and then censored. Survival curves were created using the
Kaplan–Meier method to present overall mortality and the composite
of mortality and HTX stratiﬁed by disease etiology.
The prognostic value of single clinical variables was assessed using
Cox regression by calculating adjusted hazard ratios (HR) with 95%-
conﬁdence intervals (95% CI), using the data from the total observation
time. The effects were estimated for the both groups of ICM and DCM
patients, and the difference between these groups was assessed with
the Wald test for an interaction term in the model. Four basic predic-
tors—age (linear for patients ≥ 50 years), gender, NYHA III/IV and
LVEF≤ 30%—were adjusted for center of patient inclusion and for inclu-
sion period (2001–2009 vs. 1995–2000) and their interaction. For the
further potential predictors of mortality, effects were adjusted for
these basic predictors as well as center and inclusion period.
In order to assess the discriminatory ability of prediction models in-
cluding all relevant available clinical variables by ROC curves and C sta-
tistics etiology-speciﬁc multivariable Cox regression models were
developed. The same variables were included for both etiologies, and
only variables with p N 0.15 in both models were removed. Three vari-
ables, QRS duration, anemia and NTproBNP were not considered for
this multivariable analysis due to the incomplete composition of data
sets in the overall cohort, speciﬁcally between the years 1995 and
1999, and means were imputed for missing values of the other covari-
ates. All effects were adjusted for center and inclusion period, so we
used a “minimal model” including only center and inclusion period as
factors for comparison purposes. In this setting, ROC curves depend on
the time for which the prediction is made, and they were calculated
for 5 years after index discharge using the method of Heagerty et al.
[20]. Estimates of the C-statistics and their difference between the full
models and the minimal models together with their standard errors
were calculated using the method of Uno et al. [21]. All tests were
two-tailed and a p-value of less than 5%was regarded statistically signif-
icant. Statistical analysis was performedwith SAS version 9.2 (Cary, NC,
USA).
3. Results
3.1. Characteristics and pharmacotherapy stratiﬁed by etiology of CHF
Of all 2318 patients who fulﬁlled the inclusion criteria, those suf-
fering from ICM (47.5%) presented in a more severe NYHA clinical
stage and more often carried well known risk factors commonly as-
sociated with CAD: Diabetes, hyperlipidemia, arterial hypertension
and smoking. These patients also more likely had renal insufﬁciency
in comparison to the group of patients with DCM (15.5% versus 9.8%,
respectively, p b 0.0001). A comparison of age distribution between
the two groups is presented in Fig. 1. Patients in whom DCM was
the underlying cause of heart failure (52.5%), were signiﬁcantly
Fig. 1. Smoothed density curves of the age distribution of patients according to the under-
lying etiology of heart failure. The C-statistic estimates the probability that a patient with
ICM is older than a randomly chosen patient with DCM (c = 0.694).
Table 2
Medical therapy.
ICM (n =
1100)
DCM (n =
1218)
p-value OR (95%-CI)
Medication at discharge
ACE-I or ARB 94.3% 96.6% b0.01 0.58 (0.39–0.87)
BBL 68.4% 67.0% n.s. 1.07 (0.89–1.27)
Aldosterone antagonists 35.0% 42.8% b0.001 0.72 (0.61–0.85)
Loop diuretics 70.8% 70.7% n.s. 1.01 (0.84–1.21)
Digitalis 52.2% 65.1% b0.0001 0.58 (0.49–0.69)
Aspirin 41.4% 14.4% b0.0001 4.19 (3.43–5.13)
Anticoagulant therapy 53.4% 65.4% b0.0001 0.61 (0.51–0.72)
Statins 65.7% 25.1% b0.0001 5.70 (4.76–6.83)
ICM: ischemic cardiomyopathy; DCM: dilated cardiomyopathy; ACE-I: angiotensin-
converting enzyme inhibitor; ARB: angiotensin receptor blocker; BBL: beta-blockers.
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65.3 years in those with ICM, p-value b 0.0001) and were more likely
female (24.6% in DCM versus 18.1% in ICM, p b 0.001). Further, those
with DCM were more likely to have chronic obstructive pulmonary
disease (COPD), atrial ﬁbrillation and LBBB. These patients more fre-
quently presented with more severely impaired ejection fractions
measured in echocardiography, yet with fewer limitations in func-
tional capacity assessed by a 6-min walk test. Patient demographics
and clinical characteristics are described in more detail in Table 1.
Regarding pharmacotherapy according to heart failure guidelines,
high percentages of beta-blockers (BBL), angiotensin-converting en-
zyme inhibitors (ACE-I) and angiotensin II receptor blockers (ARB)
prescribed at discharge were found throughout both cohorts. Yet in
direct comparison, the proportion of DCM patients receiving ACE-I/
ARB, aldosterone antagonists, digitalis or oral anticoagulation wasTable 1
Baseline demographic and clinical characteristics.
ICM (n = 1100)
Secondary center [%] 47.1%
Age [years/IQR] 65.3 (57.1–71.7)
Female gender [%] 18.1%
Functional class [%]
NYHA class II 37.6%
NYHA class III 50.2%
NYHA class IV 12.1%
Severely impaired LVF (EF ≤ 30%) [%] 67.1%
Moderate/severe mitral regurgitation [%] 25.7 %
Heart rate [bpm] (IQR) 75 (65–87)
Atrial ﬁbrillation [%] 15.8%
LBBB [%] 26.2%
Diabetes [%] 31.0 %
COPD [%] 28.4 %
Hypercholesterolemia [%] 58.7 %
BMI 26.4 (24.1–29.0)
Sodium [mmol/l] 139 (137–141)
NT-proBNP [ng/l] 1781 (735–4387)
Creatinine N 1.5 mg/dl [%] 15.5 %
Hemoglobine [g/dl] 13.7 (12.3–14.9)
ICD/CRT [%] 24.0%
Six-minute walk test [m] 428 (344–493)
ICM: ischemic cardiomyopathy; DCM: dilated cardiomyopathy; OR: odds ratio; IQR: interquarti
ventricular ejection fraction; bpm: beats perminute; LBBB: left bundle branch block; ICD: implan
body mass index; COPD: chronic obstructive pulmonal disease; *NYHA: III-IV vs. II, II-III vs. IV.signiﬁcantly higher, whereas the proportion of patients with ICM
who received aspirin and statin therapy was expectably larger than
in the cohort of patients with DCM (Table 2).
3.2. Mortality and need for heart transplantation
During the follow-up period of up to 14.8 years (mean = 53.1,
SD = 43.5 months; 10,264 patient-years) 991 (42.8%) patients died
and 197 (8.5%) patients received HTX. The median interval
between index visit and HTXwas 19.6months (IQR=7–40months).
Patient status at 5 years was available for 949/1100 (86.3%) patients
of the ICM cohort (425 deaths, 67 HTX, 457 survivors) and 1079/
1218 (88.6%) patients with DCM (322 deaths, 104 HTX, 653 survi-
vors) who entered the study. Kaplan–Meier survival curves illustrat-
ing 5-year survival stratiﬁed by the underlying etiology of CHF are
shown in Fig. 2a. In the group of patients suffering from ICM, unad-
justed survival rates were 85.1% (95% CI: 82.8–87.1%) at 1 year,
67.5% (95% CI: 64.4–70.4%) at 3 years and 53.4% (95% CI: 49.9–
56.7%) at 5 years. Overall survival was higher in the group of patients
suffering from DCM (log rank test p b 0.0001). Unadjusted survival
rates in this patient cohort were 91.2% (95% CI: 89.4–92.7%) at
1 year, 77.8% (95% CI: 75.2–80.2%) at 3 years and 68.1% (95% CI:
65.1–71.0%) at 5 years, respectively. Accordingly, for the compositeDCM (n = 1218) p-value OR (95%-CI)
29.5 % b0.0001 2.13 (1.80–2.53)
56.8 (48.4–64.4) b0.0001 –
24.6 % b0.001 0.68 (0.55–0.83)
b0.0001*
45.0% –
46.9% –
8.1% –
76.1% b0.0001 0.64 (0.53–0.77)
30.1 % b0.05 0.80 (0.65-0.98)
80 (70–95) b0.0001 –
21.9% b0.001 0.67 (0.54–0.84)
34.4% b0.0001 0.68 (0.56–0.82)
17.7 % b0.0001 2.09 (1.72 -2.55)
36.4 % b0.0001 0.70 (0.58–0.83)
27.7% b0.0001 3.72 (3.10–4.45)
26.4 (23.7–29.6) n.s. –
139 (137–141) b0.05 –
1611 (627–3750) n.s. –
9.8 % b0.001 1.69 (1.29–2.22)
14.1 (12.9–15.2) b0.0001 –
15.1% b0.001 1.77 (1.44–2.19)
464 (378–528) b0.0001 –
le range; NYHA: NewYork Heart Association; LVF: systolic left ventricular function; EF: left
table cardioverter-deﬁbrillator; CRT: cardiac resynchronization therapydeﬁbrillator; BMI:
Fig. 2. Kaplan–Meier survival curves: 5 year follow up. a: Endpoint mortality. Survival
curves not adjusted. HTX censored. Kaplan–Meier curve of 5-year survivalwas signiﬁcant-
ly lower amongpatientswith ICM compared to thosewith DCM as the underlying cause of
CHF (log rank test p b 0.0001). b: Endpoint mortality or heart transplantation. Survival
curves not adjusted. Five-year event-free survival was signiﬁcantly lower among patients
with ICM compared to those with DCM as the underlying cause of CHF (log rank test
p b 0.0001).
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derlying etiology of CHF and was notably higher in the group of pa-
tients with DCM (log rank test p b 0.0001, Fig. 2b).
3.3. Multivariable predictors of mortality
Clinical characteristics associated with mortality are presented in
Fig. 3a–c. All available demographic information and baseline clinical
characteristics that potentially affected survival were analyzed. After ad-
justment, advanced age, EF≤ 30%, NYHA functional class III/IV, BMI b 25,
renal insufﬁciency, hyponatremia,moderate/severemitral regurgitation,
anaemia (WHO deﬁnition) and NTproBNP values N 2000 pg/ml were
found to be associatedwith shorter survival time in both patient cohorts.
In contrary, among all patients, time to death was not signiﬁcantlyFig. 3. Predictors ofmortality. a: Hazard ratios of single predictors for all-causemortality by etio
of single predictors for all-causemortality by etiology, adjusted for age (linear N 50 years), gende
cause mortality by etiology, adjusted for age (linear N 50 years), gender, LVEF, NYHA class, cenprolonged in females and in those with hyperlipidemia (Fig. 3a, b). Fur-
ther, diabetes, atrial ﬁbrillation, heart rate ≥ 80/min, a wide QRS com-
plex (N120 ms), LBBB and COPD failed to carry predictive power in
patients with DCM (Fig. 3c). Among all variables investigated, an
NTproBNP value of N2000 pg/ml was the most strongly associated pre-
dictor of reduced survival in both groups followed by hyponatremia
and NYHA functional class III/IV. In multivariable analysis, all the above
mentioned clinical variables except for hyperlipidemia proved to be in-
dependently associated with worse survival in patients suffering from
ICM (Table 3). Yet when assessing patients with DCM in a multivariable
model, diabetes, COPD, LBBB, atrial ﬁbrillation and increased resting
heart rate of ≥80 bpm failed to carry independent predictive power. Of
the characteristicswhich correlatedwith improved survival, female gen-
der and hyperlipidemia did not attain statistical signiﬁcance.
The ROC curves of the multivariable models as predictors for 5-year
mortality are shown in Fig. 4a and b. The C-statistic for ICM is 0.70 and
its difference from the corresponding minimal model including only
center and inclusion period as factors is 0.12 (95%-CI 0.09–0.14). For
theDCMgroup, theC statistic is 0.67 and its difference from theminimal
model is 0.09 (95%-CI 0.06–0.12), which falls short of reaching a statis-
tically signiﬁcant difference from ICM (p = 0.17).
4. Discussion
In this present analysis we report differences in clinical predictors of
mortality in a cohort of 2318 ambulatory CHF patients who were strat-
iﬁed according to the underlying cause of systolic CHF. Themain ﬁnding
of our study is that in CHF patients seen in daily clinical practice, with
impaired systolic function under individually optimized pharmacother-
apy, a comparably limited number of clinically-derived parameters are
available to clinicians for prognostication of survival when DCM is the
underlying etiology of the disease.
Interestingly, unlike in many other diseases, most clinical trials in
CHF have investigated generalized populations of systolic dysfunction
without incorporating potential effects of primary pathophysiological
processes behind the syndrome. Yet with sufﬁcient knowledge of
preconditional heterogeneity of this systolic phenotype of CHF and
with numerous aspects of personalized medicine (genomic, proteomic
andmetabolomic scores) on the horizon, it seems almost inappropriate
to guide treatment in CHF without adequate accommodation of a deci-
sive factor such as etiology.
Some previous trials have performed etiology-oriented analysis of
long-term survival in CHF. Whereas the majority of these studies
showed a clear beneﬁt of non-ischemic origin of CHF [22–25], Studies
of Left Ventricular Dysfunction (SOLVD) and a large population-based
study failed to demonstrate a negative inﬂuence of ischemic heart dis-
ease or previous myocardial infarction on survival [26,27]. Reasons for
these conﬂicting results are presumably diverse. They may partially lie
in the incoherent composition of inclusion criteria in these trials or in
the diagnostic accuracy achieved by the chosen imaging modality. Fur-
ther, as themajority of trials which addressed the effect of disease path-
ogenesis on mortality were performed in the early 1990s, the
percentage of patients who received BBL at the time of investigation
ranged broadly between the respective studies. Consequentially, to en-
able comparisons of our present cohort study with results of these prior
analyses including the observed mortality rates, the evolution in CHF
treatment over the last fourteen years needed consideration. We there-
fore adjusted our regression analysis for the center in which the patient
was treated (tertiary versus secondary center) and for the inclusion pe-
riod. By this, we attempted to manage previously reported interactions
of institutional settings and treatment patterns over time [28–32]. To
date, Frazier et al. have performed the largest available meta-analysislogy, adjusted for center and inclusion period (1995–2000 vs. 2001–2008). b: Hazard ratios
r, LVEF, NYHA class, center and inclusion period. c:Hazard ratios of single predictors for all-
ter and inclusion period.
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Table 3
Multivariable hazard ratios for 5-year mortality by etiology.
Variable Multivariable HR (95%-CI)
ICM DCM
Age [per 10 years above 50] 1.46
(1.30–1.63)
1.49
(1.31–1.68)
Female gender 0.97
(0.76–1.24)
0.80
(0.63–1.02)
EF ≤ 30% 1.24
(1.01–1.52)
1.33
(1.03–1.71)
NYHA III/IV at discharge 1.49
(1.23–1.80)
1.61
(1.32–1.97)
BMI b 25 1.32
(1.09–1.60)
1.22
(0.99–1.49)
Diabetes 1.45
(1.19–1.76)
1.12
(0.87–1.44)
Hypercholesterolemia 1 1
Creatinine N 1.5 mg/dl 1.36
(1.05–1.76)
1.53
(1.09–2.15)
COPD 1.29
(1.04–1.60)
1.02
(0.82–1.26)
Sodium b 135 mmol/l 1.73
(1.27–2.35)
1.65
(1.22–2.24)
Heart rate ≥ 80 / min 1.29
(1.06–1.57)
1.12
(0.91–1.38)
Atrial ﬁbrillation 1.41
(1.11–1.78)
0.89
(0.69–1.14)
Moderate / severe mitral regurgitation 1.28
(1.02–1.60)
1.52
(1.21–1.90)
LBBB 1.22
(0.99–1.50)
1.04
(0.85–1.26)
HR: hazard ratio; other abbreviations as in Table 1.
The effect estimates are adjusted for center and inclusion period. Variables removedby the
selection are marked with a hazard ratio of 1.
Fig. 4. Receiver operating characteristic curves formultivariable models as predictors of 5-
year mortality according to the underlying etiology of heart failure. a: Receiver operating
characteristic curves at 5 years post discharge for multivariable models as predictors of
5-year mortality in ICM patients. b: Receiver operating characteristic curves at 5 years
post discharge for multivariable models as predictors of 5-year mortality in DCM patients.
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gender in CHF [25]. The authors showed that non-ischemic etiologywas
associatedwith longer overall survival andwith longer time to the com-
posite event of hospitalization or death. As mentioned earlier, data for
the combined analysis by Frazier et al. were pooled from ﬁve random-
ized clinical trials, each of which evaluated the beneﬁt of a speciﬁc phar-
macotherapy in CHF and subsequently were subject to speciﬁc
restrictive inclusion criteria. Thus, although their results may be revela-
tory by providing insights on a large number of patients with a maxi-
mum follow up period of 901 days, they may not broadly represent
CHF patients under optimized pharmaco- and device therapy in the
“real life” setting of outpatient care. To eliminate these uncertainties,
we addressed the question on the level of daily clinical practice and
searched for inﬂuential factors of reduced survival time and time to
HTX in a multi-site registry with patients followed up to almost
15 years. As patients were cared for at specialized heart failure clinics
over a period of many years, intense outpatient care including individu-
ally optimized pharmacotherapywere ensured. In regards to index clin-
ical and demographic variables, the observations that patients with ICM
were older at the time of diagnosis (on average 8 years older that in the
group of patients with DCM) and that they presented withmore severe
clinical symptoms are of particular importance. Further, speciﬁc for pa-
tients inwhomDCMwas the underlying cause of CHF, were the ﬁndings
that the proportion of women was higher and that although these pa-
tients more likely had concomitant COPD and amore severely impaired
ejection fraction, they were less symptomatic and had higher exercise
capacity. Concerning the notably prolonged survival time in patients
with DCM in comparison to those with ICM, we conﬁrmed the ﬁndings
of Frazier et al. and of the majority of previous smaller trials which had
all been performed before BBL and ACE-I/ARB were fully adapted in to
clinical practice.
In conformity with previous trials which studied clinical risk factors
in CHF, well-known associations with impaired outcome in CHF such asadvanced age, EF≤ 30%, NYHA functional class III/IV, renal insufﬁciency
and hyponatremia sustained in our multivariable analysis of both sub-
phenotypes. Other variables were associated with shorter survival:
BMI b25 kg/m2 and moderate/severe mitral regurgitation or with
prolonged survival: female gender. However, it must be acknowledged
that the 95%-CIs of these variables crossed unity and therefore theymay
have less clinical impact. We also discovered a consistent pattern be-
tween the two etiologies in regards to NTproBNP being themost strong-
ly associated parameter followed by hyponatremia and NYHA
functional class III/IV the second most strongly associated predictors of
reduced survival. Diabetes, COPD, an increased resting heart rate of
N80 bpm, a wide QRS complex (N120 ms)—LBBB in speciﬁc and atrial
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tivariable assessment. Interestingly, raised resting heart rate, an inﬂuen-
tial co-variable in heart failure which has attracted much notice in
recent years [33–36], was among the parameters which were indepen-
dently associatedwith shorter survival time exclusively in patients with
ICM yet not in those with DCM. Despite uniform electrocardiographical
phenotypes, the differences in risk observed in this present cohort em-
phasize the diverging nature of rhythm disorders in ischemic and non-
ischemic cardiac tissue and may partially explain differences in
response to Cardiac Resynchronization Therapy (CRT) or antiarrhyth-
mic agents.
Itmay attract attention that in the present study—in contrast tomost
of other large etiology based trials [37,38]—the group of DCM patients is
larger than the ICM cohort. As HELUMA is inter alia a registry containing
data froma large specialized cardiomyopathy center,more than average
numbers of DCM patients are included in the registry.
As stated previously, this analysis demonstrates that well known
risk factors of CHF, which are commonly used to prognosticate survival
of CHF patients in clinical daily routine, are especially conclusive in
patients with ICM, whereas they are signiﬁcantly less precise when
used in with DCM patients.
The complexity of the pathophysiology of idiopathic DCM may
explain the poorer performance of classical risk factors in comparison
to ICM. Particular attention should be paid to atrial ﬁbrillation and
wide QRS complex (N120 ms) as these risk factors were signiﬁcant
prognostic factor of long-term survival in ICM in our study, yet had no
prognostic value in patientswithDCM. In this context the lack of predic-
tive signiﬁcance of atrial ﬁbrillation andwide QRS complex in DCMmay
be associated with their pre-existence without relevant LV dysfunction
in DCM, whereas in ICM, atrial ﬁbrillation and wide QRS complex most
likely result from a previous ACS event [39,40]. Interactions between
genetic and non-genetic factors play a major role in DCM and in other
heritable cardiomyopathies [41–44]. Even in cases of presumed non-
genetic DCM recent research points to underlying genetic predisposi-
tions [45,46]. As of now, further insight is needed until we can fully
understand how identiﬁed genetic variations and their modiﬁers trans-
late into patients' phenotypic signatures.
Although the HELUMA heart failure registry includes a large amount
of phenotypic information,we cannot account for additional clinical risk
factors whichwere not evaluated in our registry yet possibly contribute
to the differences found in our analysis. Our data provide new insights
into etiology-speciﬁc differences of the systolic sub-phenotype of CHF
in terms of the likelihood of rapid disease progression and mortality.
With greater understanding of the syndromic heterogeneity of CHF
and of its subphenotype-related variances in survival, more appropriate
risk discrimination models for guidance in treatment and more reﬁned
therapeutic solutions to achieve delayed progression of systolic dys-
function may soon emerge for use in everyday clinical practice.
4.1. Limitations
Although data from the participating clinics were entered in a pro-
spective manner, this present study is subject to the characteristic
shortcomings of registries. Nevertheless, its clinical practise-based ap-
proach over a period of over 14 years also implies one of themain values
of this present study. The all-comer population of CHF patients allows
for long-term analysis of those, who for various reasons, would have
been excluded by contemporary study protocols.
As this analysis is based on data provided by theHELUMA registry, in
which solely CHF patients are enrolled, it is difﬁcult tomake a statement
on a comparison between the two described collectives, ICM and DCM,
and a healthy validation cohort. Furthermore, the registry contains two
main endpoint entities, death of various reasons and heart transplanta-
tion. As there was no possibility to specify reasons for death due to the
conception of the registry, we were unable to differentiate the cohorts
according to important terms such as cardiac causes, sudden death,pump failure or other reasons. This is a serious limitation, which should
be considered in future studies and registries in these patients.
There are some baseline parameters, which indicate a therapy not
according to current guidelines, such as ICD/CRT implantation which
was highly underrepresented in both collectives (30% in a high-risk
cohort). There are multiplex reasons, as there are individual decisions
being weighed for every single patient, such as common operability,
especially because of limiting diseases, age, nutritional condition, etc.
Finally, the evidence based need for ICD/CRT therapy may not have
been appropriate for the individual patient and therefore—after careful-
ly considering every single aspect—was not carried out.
An additional negative aspect of our longer term approach is the fact
that we were unable to include blood levels of NTproBNP in patients
who were treated at the secondary hospital before the year 1999 and
results of 6-minwalk tests into ourmultivariablemodel due the skewed
availability of these data over the entire inclusion period. Besides this,
the prognostic value of risk factors we presented may differ in female
patients. Only 21.5% of the overall cohort was women and thus, sex-
speciﬁc prognostic testing was not possible. Further, though outpatient
care offered by the participating hospitals is offered to all patients,
patient selection may be biased by referring physicians, who may
have considered only certain patients in need of more intense care
through specialized heart failure clinics. Since the participating hospi-
tals are located in geographically close communities of Germany, the
majority of included patients were mainly of white Caucasian origin.
The results obtained from our study may therefore not be transferable
across all ethnicities or be equally applied to all racial backgrounds. In
this present analysis we did not evaluate the exact dosages of guideline
adherent pharmacotherapy or censor patients who received an im-
plantable cardioverter-deﬁbrillator (ICD) or Cardiac Resynchronization
Therapy (CRT). As these factors have shown to provide substantial ad-
vantages in survival, a general limitationmay exist regarding the overall
outcome. Lastly, as of this writing, the etiology-oriented predictors of
mortality detected in our study have not been validated in other inde-
pendent CHF populations. Only by suchmeasures canwe deﬁnitely con-
ﬁrm the generalizability of the derived prediction models.4.2. Conclusion
This study demonstrates the marked disparity between the two
main etiologies of CHF with regards to the prognostic value of clinically
derived risk factors. Independent predictors for mortality were risk fac-
tors well known to be associated with reduced survival time in patients
with CHF in general. However in multivariable analysis, the overall
number of contemporary clinical variables associated with mortality
in patientswith DCMwas lower, implicating a primary pathophysiology
less modiﬁable through renowned risk factors. It may be assumed that
traditional and routinely applied models predict long-term survival
accurately for patients suffering from ICM. Although these models are
transferred unaltered to DCMpatients, there is no evidence of their pre-
cision in predicting mortality for this underlying etiology. In the future,
the need to create separate predictive models for the various causes of
CHF may occur to ensure reliable assessment of long-term survival for
each etiology. The results of this study reveal the beneﬁt of an etiolo-
gy-speciﬁc multivariate prognostic model and improve accuracy of sur-
vival estimations in CHF.
Furthermore, there is a chance that based on the development of
adjusted risk factor models, new pathways in treatment of CHF will
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